Method and system for combined energy therapy profile

Information

  • Patent Grant
  • 9011336
  • Patent Number
    9,011,336
  • Date Filed
    Wednesday, May 7, 2008
    16 years ago
  • Date Issued
    Tuesday, April 21, 2015
    9 years ago
Abstract
A method and system for treating tissue with a combined therapy profile is disclosed. In one exemplary embodiment, ultrasound energy is used to treat numerous depths of tissue within a region of interest and the spatial and temporal properties of the ultrasound energy are varied for more effective treatment. The method and system of the present invention are configured to treat all of the tissue from the surface on down and not spare intervening tissue.
Description
FIELD OF INVENTION

The present invention is directed to a method and system for treatment utilizing energy such as ultrasound energy. Specifically, the present invention is directed at treating tissues at various locations with ultrasound energy wherein the ultrasound energy is applied at different levels at different locations within the tissue.


BACKGROUND OF THE INVENTION

Energy, such as ultrasound energy, can be applied to treat tissue or perform traditionally invasive procedures in a non-invasive manner. The application of ultrasound energy provides both thermal and/or mechanical effects that help treat certain ailments such as acne and enable many traditional invasive procedures to be performed non-invasively.


Current ultrasound devices provide energy to tissue within a region of interest. The energy is emitted from an ultrasound system and travels a certain depth within the tissue and has an effect on the tissue. The effect can be ablative, coagulative, non-ablative, or non-coagulative and is generally caused by the thermal and/or mechanical properties that ultrasound has on tissue. Thermal properties increase the temperature of the tissue at the region of interest while the mechanical effects are achieved by cavitation, streaming, radiation force, and other natural mechanical effects of ultrasound.


Further, ultrasound energy has certain spatial and temporal properties when it is applied to the region of interest. The “temporal” properties refer to the time that the ultrasound energy is applied while the “spatial” properties refer to the space within the tissue that is affected by the ultrasound energy at a specific moment in time.


While effective, existing ultrasound devices only affect a specific portion of the tissue at a certain depth within the region of interest based upon the configuration of the ultrasound device. For example, an ultrasound device might be configured to affect an area five millimeters below the surface of the skin. The tissue from the surface of the skin to the depth of five millimeters is spared and not treated by the ultrasound energy. Sparing these intervening spaces of tissue hinders the overall beneficial effect of ultrasound as treatment of this intervening tissue increases ultrasound treatment's overall efficacy.


Therefore, it would be beneficial to provide an ultrasound device and treatment method that treats multiple areas of tissue in a region of interest including intervening tissue and even the distal layer of tissue. It would also be advantageous to provide a system and method that treated numerous depths of tissue by varying the spatial and temporal effects of ultrasound at different depths such has having ablative or coagulative ultrasound applied to certain depths of tissue while non-ablative ultrasound is applied to other depths of tissue.


SUMMARY OF INVENTION

A method and system for creating a combined energy profile by providing energy to tissue at different locations within a region of interest is provided. In an exemplary embodiment, the energy is ultrasound energy and it is provided at various locations and/or depths to conduct traditionally invasive procedures non-invasively by utilizing the thermal and/or mechanical effects of ultrasound energy. In certain exemplary embodiments, ultrasound energy with different spatial and temporal characteristics is applied to a region of interest (“ROI”) to treat the ROI.


An exemplary system and method that provides ultrasound energy with different spatial characteristics creates different effects at different locations and/or depths within the tissue being treated. For example, ultrasound energy may be applied with a larger geometric shape at one depth and a smaller geometric shape at another depth without sparing the intervening tissue from the skin's surface to the deepest depth of ultrasound penetration. In certain exemplary embodiments, the application of ultrasound energy with differing spatial characteristics can increase the overall temperature at the ROI with less energy use.


Further, the time that the ultrasound energy is applied can also change the effects of the ultrasound energy at different tissue locations or depths. In one exemplary embodiment, energy can be applied at longer times at certain depths and shorter times at other depths without sparing intervening tissue. These temporal changes in the application of ultrasound energy can affect the results of the ultrasound treatment at the ROI.


In certain exemplary embodiments, both the temporal and spatial characteristics of ultrasound energy effect the overall treatment provided. In yet other embodiments, only the temporal changes effect the treatment. Still in yet other embodiments, only the spatial characteristics effect the treatment.


Various different ultrasound systems configured to provide the combined energy profile fall within the scope of the present invention. In one exemplary embodiment, an ultrasound system with a transducer probe comprising different transduction elements is provided. Each transduction element is capable of producing ultrasound energy for different time lengths and with a different geometric pattern.


Applying ultrasound energy at different spatial and temporal levels increases the temperature and/or utilizes the mechanical effects of ultrasound energy throughout the entire ROI from the surface of the skin to the deepest location of ultrasound energy penetration without sparing intervening tissue. Treating a ROI with a combined energy profile can be highly effective at treating certain ailments.


For example, acne at a ROI can affect multiple depths of tissue and acne can be treated at the top of the tissue where pimples form by applying ablative ultrasound energy to the top portion of the tissue. The various subcutaneous tissues below the surface of the skin can also be treated with non-ablative ultrasound energy to treat individual pilosebaceous glands that cause the acne.





BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter of the invention is particularly pointed out in the concluding portion of the specification. The invention, however, both as to organization and method of operation, may be best understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals.



FIGS. 1A-1B illustrate a schematic diagram of tissue that can be treated in accordance with an exemplary embodiment of the present invention;



FIG. 2 illustrates a graph showing the temperature increase over a given time period in accordance with an exemplary embodiment of the present invention;



FIGS. 3A-3C illustrate graphs that show the spatial and temporal changes of ultrasound energy at various tissue depths in accordance with one exemplary embodiment of the present invention;



FIG. 4 illustrates a block diagram of a treatment system in accordance with an exemplary embodiment of the present invention;



FIG. 5 illustrates an annular transducer array in accordance with an exemplary embodiment of the present invention;



FIG. 6 illustrates an annular transducer array in accordance with an exemplary embodiment of the present invention;



FIGS. 7A-7D illustrate cross-sectional diagrams of an exemplary transducer in accordance with various embodiments of the present invention; and



FIGS. 8A-8C illustrate block diagrams of an exemplary control system in accordance with exemplary embodiments of the present invention.





DETAILED DESCRIPTION

The present disclosure may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, certain embodiments may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions and be capable of emitting ultrasound energy for imaging or treatment or combinations thereof.


With reference to FIGS. 1A, 1B, and 4, a method and system is disclosed for providing a combined therapy profile to several tissue depths in a ROI. In one exemplary embodiment, an energy emitting system such as an ultrasound system 10 can be used to provide therapeutic treatment to two or more tissue depths by emitting ultrasound energy with different spatial and temporal properties to different depths or areas within ROI 12. System 10 and the related method of the present invention apply ultrasound energy 16 to ROI 12 at the surface of the patient's skin and ultrasound energy 16 travels from the surface to a location within ROI 12 and treats all the tissue within ROI 12 with a combined energy profile without sparing any of such tissue.


With particular reference to FIGS. 1A and 1B, ROI 12 can comprise an inner treatment region, a superficial region, a subcutaneous region of interest and/or any other region of interest in between an inner treatment region, a superficial region, and/or a subcutaneous region within a patient. In various exemplary embodiments, ROI 12 comprises at least one pilosebaceous unit 14 and an associated sebaceous gland. Throughout this application, reference to a “pilosebaceous unit” includes all the contents of the pilosebaceous unit 14 and related sebaceous gland.


Further, ROI 12 can include multiple layers or types of tissue such as, but certainly not limited to, skin, fat, muscles, tendons, cartilage, ligaments, the superficial muscular aponeurotic system, other fibrous or connective tissues, the dermis, epidermis, organ tissues, mucous membrane, hair bulb, hair shaft, hair follicle between the hair bulb, apocrine sweat glands, eccrine glands lying within the dermis, fat or muscle, tumors, and/or any other tissue of interest.


Further, ROI 12 can be limited to specific depths such as 0-20 millimeters or it can deeper into the body. In one exemplary embodiment, ROI 12 is at a depth in the range of 0.2 to 8 millimeters while in another exemplary embodiment, ROI 12 is at a depth of 0.3 to 6 millimeters.


Alternatively, ROI 12 can be limited to the surface of the skin or immediately below the surface, or areas between the surface and greater depths within the body. While only one ROI 12 is depicted, a plurality of ROIs 12 can be treated by the system in an exemplary embodiment. Also, other glands can be treated by the method and system of the present invention. These glands comprise sweat glands, endocrine glands, and other glands. Therefore, the method and system of the present invention can be used to treat acne, oily skin and hair, as well as other ailments. ROI 12 may also consist of one more organs, such as skin, or a combination of tissues either superficial or deep within the body.


In an exemplary embodiment, energy such as ultrasound energy 16 is emitted from system 10 at multiple depths throughout ROI 12 to target numerous depths of tissue within a specific ROI 12. In addition to ultrasound energy 16, other energy forms such as photon-based energy such as laser energy, radio frequency energy (certain examples of radio frequency include monopolar and bipolar radio-frequency current), mechanical energy such as massage or other vibration-based energy and other energies can be used and fall within the scope of the present invention. Further, various light energy can be used in connection with ultrasound energy 16 to treat ROI 12. Certain exemplary frequencies of light are in the range of 400 nm to various wavelengths for infra-red light can be used.


For example, blue light at a wavelength of approximately 400 to 450 nm can be used to pre-treat ROI 12 before the application of ultrasound energy 16 or blue light of this wavelength can be used with ultrasound to increase the efficacy of treatment. In another embodiment, visible light in the range of 600 to 1350 nm can be used with the ultrasound during treatment.


Multiple depths of tissue within ROI 12 are treated from the surface down to the deepest point of ultrasound energy penetration and no intervening tissue is spared in one embodiment of the present invention. For example, ultrasound energy 16 from one source may have a spatial characteristic of affecting an area 15 millimeters in diameter 5 millimeters below the surface of the skin while ultrasound energy from another source may affect an area 9 millimeters below the surface of the skin with an area of 30 millimeters in diameter.


Various different time frames for ultrasound energy 16 emissions can be used in the present invention. Certain exemplary time frames include ranges of approximately fifty microseconds to fifteen minutes. Another exemplary time range is five hundred milliseconds to sixty seconds and yet another exemplary time frame is one second to sixty seconds. Numerous other time frame ranges can be implemented depending on the particular treatment application desired.


Moreover, the temporal characteristics of ultrasound energy 16 affecting ROI 12 can be changed for each location within the total area that comprises ROI 12. For example, ultrasound energy 16 that is directed 5 millimeters below the surface of the skin may only be emitted for 10 seconds while ultrasound energy 16 that is directed 9 millimeters below the surface of the skin may be emitted for 20 seconds. In other exemplary embodiments, these temporal properties of ultrasound energy 16 can be changed so that ultrasound energy 16 is pulsed for a certain duration. The time duration of each pulse of ultrasound energy can be changed as well. For example, ultrasound energy 16 can be emitted in 20 one second pulses at a depth of 5 millimeters below the surface of the skin and at 10 four second pulses at a depth of 10 millimeters below the surface of the skin. The different spatial and temporal properties of ultrasound energy 16 can be changed for each location and/or depth within a total ROI 12 to create a combined temperature profile.


As depicted in FIG. 1A and according to an exemplary embodiment of the present invention, ultrasound energy 16 is emitted and reaches different levels of tissue. As shown, some ultrasound energy 16 reaches a depth within subcutaneous fat at location 18. At locations 20 and 22, ultrasound energy 16 reaches a level to place it directly in the area of pilosebaceous unit 14 and its contents. As show in FIG. 1B, ablative energy may be applied near the surface while non-ablative energy is applied at non-ablative levels at deeper depths.


There are numerous possible medical applications for the system and method of the present invention. Many treatments effectuated by the method and system of the present invention result from increased blood perfusion at ROI 12 and the associated benefits of increased perfusion. For example, the application of ultrasound energy 16 at a specific location within ROI 12 can result in localized perfusion.


The increased perfusion can assist and/or stimulate numerous effects such as epidermal stimulation and a processes known as “colleganesis” or increasing the amount of collagen at ROI 12. Increasing perfusion also brings more of the body's natural repair cells (as discussed herein) to ROI 12 and that can assist with cell regeneration as well as other cellular repair processes and fibroblast activity. Increasing perfusion at ROI 12 also increases epidermal thickness and dermal mass. Other benefits from increasing blood perfusion are better skin tone and texture.


The application of ultrasound energy 16 also decreases certain conditions or ailments. For example, applying ultrasound energy 16 decreases pore size and blemishes (whether the blemishes are associated with acne or not). Other ailments or conditions that can be decreased by the application of ultrasound energy include, but are certainly not limited to, vascular defects, superficial wrinkles, uneven complexion, dischromia/blotchiness, and certain gland activity (such as the sebaceous gland).


The application of ultrasound energy 16 at higher levels powerful enough to cause ablation or coagulation at the skin surface or at greater depths within ROI 12 produces other effects. These effects can comprise the removal of warts, scars, moles, corns, calvi or calluses from ROI 12. Shaving bumps or “pseudofolliculitis barbae” can be treated or prevented with the method and system of the present invention. In this regard, the bumps can be ablated from the human body by applying ultrasound energy 16 at ablative levels or the bumps can be treated or prevented by applying ultrasound energy 16 at deeper depths at non-ablative levels to increase perfusion to the area with shaving bumps to treat the cause of the shaving bumps such as infected glands. Moreover, the application of ultrasound energy 16 at ROI 12 can create lesion by heating or burning tissue, and/or cavitation within ROI 12.


In the examples set forth above, while certain tissues are being removed from ROI 12 by applying ultrasound energy 16 at ablative levels, ultrasound energy 16 at lower, non-ablative levels can be applied deeper within ROI 12. For example, ultrasound energy 16 can be applied at ablative or coagulative levels to remove a mole from the surface of the skin while lower, non-ablative and non-coagulative ultrasound energy can be applied at deeper depths to increase blood perfusion at those depths. Changing the temporal and spatial parameters of the application of ultrasound energy 16 at different locations determines whether or not it is applied at an ablative or non-ablative level.


Various other effects resulting from the application of ultrasound energy 16 at ROI 12 comprise peaking out inflammation or edema at ROI 12. Further, increased angiogenesis (the growth of blood vessels) can result by the application can result from applying ultrasound energy 16 to ROI 12.


As described herein, applying ultrasound energy 16 at ROI 12 can have curative and non-curative effects. Further, while numerous examples of treatments have been described herein, other treatments can be effectuated and fall within the scope of the present invention. Further, in one exemplary embodiment, two or more types of treatment can occur simultaneously at ROI 12. For example, a mole can be burned off at the skin's surface while increased angiogenesis occurs at a deeper level within the tissue at ROI 12.


In an exemplary embodiment, the spatial and temporal properties of ultrasound energy 16 can be changed to effectively treat acne and the associated pilosebaceous unit 14. Specifically, ultrasound energy 16 can be applied with spatial and temporal properties that result in ablation of tissue at the surface of the skin by raising the temperature at the skin's surface above 60° C. for approximately one second, which causes ablation, or above any time-temperature threshold. According to one exemplary embodiment, ultrasound energy 16 is applied at non-ablative levels below the surface in ROI 12 near pilosebaceous unit 14. Ultrasound energy is applied at non-ablative levels by varying the spatial and temporal characteristics of ultrasound energy 16 to levels where they do not raise the temperature above ablative levels or 60° C.


Further, with reference to FIG. 1B, applying ultrasound energy 16 at various depths within ROI 12 can create a zone within the tissue where ablation or coagulation may occur. Another region (either above or below), can receive ultrasound energy at non-ablative levels with the same ROI 12. Treating areas or zones within ROI 12 with different levels of ultrasound energy provides a combined treatment effect as explained herein.


In another exemplary embodiment, ultrasound energy 16 is applied at different depths or locations within ROI 12 non-simultaneously. In this exemplary embodiment of non-simultaneous ultrasound energy 16 emissions, ultrasound energy 16 from one source can be applied to raise the temperature at certain predetermined depth to a certain level. Ultrasound energy from another source aimed to target an area within ROI 12 above the first area targeted by the first source. Because the first area in ROI 12 is already heated and adjacent to the second area, the second area is in effect pre-heated and less ultrasound energy 16 is required to heat the second area. By utilizing ultrasound energy 16 from two sources and applying it in this stepped form, less overall energy is needed than if energy was used from a single source.



FIG. 2 illustrates a graph of this type of temperature increase. As shown on the graph, the temperature is represented on the “y” axis while the time is represented on the “x” axis. Line 17 represents the temperature increase caused by a first emission of ultrasound and line 19 represents the temperature increase caused by a second emission of ultrasound. As shown in this exemplary embodiment, the temperature is raised to a new base or threshold level of 40° C. by application of the first emission of ultrasound energy 16. This increased threshold enables the second emission of ultrasound to raise the temperature to a still higher level of 50° C. as shown by line 19.



FIGS. 3A-3C illustrate various different examples of the spatial and temporal applications of energy such as ultrasound energy 16 in different exemplary embodiments of the present invention. With particular reference to FIG. 3A, temporal changes for ultrasound energy 16 applied to fat and ultrasound energy 16′ applied to the skin and epidermis can vary. The “Y” axis represents the amount of energy applied within ROI 12 and the “X” axis represents the time period that ultrasound energy 16 is applied.


In this example, ultrasound energy 16′ is applied for a longer time period near the skin and epidermis while ultrasound energy 16 is applied for a short time period in the subcutaneous fat of ROI 12. The temporal characteristics of ultrasound energy 16 can be changed in other exemplary embodiments of the present invention depending on the treatment desired.


With reference now to FIG. 3B, the spatial properties of ultrasound energy within ROI 12 at a given moment in time are shown. The “Y” axis represents the treated volume of tissue while the “X” axis represents the depth of ultrasound energy 16. As shown in this exemplary embodiment, ultrasound energy 16 applied near the skin can treat a volume less than the volume treated by ultrasound energy 16′ applied to the subcutaneous fat. The spatial properties illustrated in this graph can also be varied depending on the treatment desired in other exemplary embodiments of the present invention.



FIG. 3C also depicts a spatial distribution of ultrasound within (and proximal to) ROI 12 at a given period of time. As shown, there are two different patterns of ultrasound energy 16 and 16′. The pattern of ultrasound energy shown as 16 is deep and wide within ROI 12 while the pattern shown by 16′ is long and narrow and affects the upper portion of tissue in ROI 12. The different patterns of ultrasound energy can be applied by utilizing two different transduction elements 50 as explained herein. In one exemplary embodiment, the patterns are applied simultaneously within ROI 12 and in another exemplary embodiment the patterns are applied at different times. When the patterns are applied at different times, the pattern of ultrasound energy 16 can be used to increase the base temperature of ROI and increase the effect of the pattern of ultrasound energy 16′ as explained above.


The application of different levels of ultrasound energy 16 at different depths of tissue creates a combined therapy profile at ROI 12. For instance, instead of merely treating acne by targeting pilosebaceous unit 14 and surrounding area with energy at ablative or non-ablative levels (as described in co-pending U.S. patent application Ser. Nos. 11/163,177 and 11/738,682 entitled Method For Treating Acne and Sebaceous Glands and Method and System for Non-Ablative Acne Treatment and Prevention respectively wherein both such applications are herein incorporated by reference in their entirety) to destroy or otherwise effect pilosebaceous unit 14 and its contents, all of the tissue at ROI 12 can be targeted to treat and prevent acne or other ailments.


For example, pilosebaceous unit 14 can be treated with ablative levels to destroy it and prevent unwanted sebum production. With the pilosebaceous gland destroyed or otherwise inhibited, sebum production is halted and future acne is prevented from developing. But, scarring, scars, blackheads, whiteheads, cysts, and scarring may still be present at the top layers of the skin such as the dermis. These layers of tissue can be treated by the application of ultrasound energy 16 at lower, non-ablative, and non-coagulative levels than what is applied at the depth of pilosebaceous unit 12.


Applying ultrasound energy 16 at lower levels at the surface of the skin heats the surface. The body's natural reaction to this increased temperature at ROI 12 is to increase blood perfusion to the ROI 12. The increased blood perfusion delivers more blood to ROI 12. The increased blood at ROI 12 results in increased number of repair cells contained within the blood to be delivered to ROI 12. Specifically, the more blood that flows to ROI 12, the more fibroblast cells and other therapeutic leucocyte cells (white blood cells) such as lymphocytes, macrophages, and neutrophils are at ROI 12 to treat current acne and prevent future acne from developing. The repair cells treat existing acne by helping acne lesions heal faster. Future acne is prevented because more nutrients at ROI 12 are able to fight acne-causing bacteria such as P-acnes.


Therefore, in this example, acne is treated by targeting multiple tissue depths at ROI 12. The depth within ROI where pilosebaceous unit 14 is located is treated with ultrasound energy 16 at one level to cease sebum production to prevent future acne from developing. Moreover, the layer where the effects of acne are seen (at the skin) is also treated with ultrasound energy 16 to help heal the scars and visible effects of acne.


In another exemplary embodiment, the temperature range within the depths of tissue can be reversed. In this exemplary embodiment, energy such as ultrasound energy 16 is applied at ablative or coagulative levels at the surface of the skin and at lower, non-ablative and non-coagulative levels at deeper depths. In this exemplary embodiment, a mole or cyst can be “burned” off of the skin at the ROI while the application of energy at deeper depths can cause increased blood perfusion which heals the area once the mole or cyst is removed and/or treated.


Applying energy such as ultrasound energy 16 at multiple depths and at different levels simultaneously treats all the tissue at the ROI 12 with the thermal and/or mechanical effects of ultrasound. The thermal effects raise the temperature above the body's normal temperature. These temperature ranges can be in whatever range needed to affect a particular result. According to the present invention, a certain amount of ultrasound energy 16 can be applied at a pre-determined depth to raise the temperature at that depth to achieve a certain result. Certain zones with a given temperature can be created at various levels of tissue depending on the level of energy provided.


For example, it might be necessary to raise the temperature to fifty degrees or more at the surface and dermal layer of tissue to burn off a mole, tumor, or other piece of unwanted skin or tissue. During this application of ultrasound energy 16, it may also be desirable to raise the temperature at a deeper depth much lower, to only five or ten degrees above the body's normal temperature to achieve a result such as increased blood perfusion. The lower temperature at one zone or layer within the tissue and higher temperature at another zone treats the entire ROI 12.


Besides temporal changes at various depths within the tissue, ultrasound energy 16 also has certain mechanical effects that can be used for treatment. In an exemplary embodiment, these mechanical effects comprise cavitation, streaming, radiation force, oscillatory forces, and sheer stress on cellular membranes of cells that comprise tissue that is being targeted. These mechanical effects such as cavitation and streaming create various forces that contact cellular walls. For example, when using the method and system of the present invention to treat acne, ultrasound energy can be used to contact the cellular walls of P-acnes and other acne causing organisms which damage or kill them. Further, these mechanical effects can also help drive medicinal creams and other agents into tissue cells to better effectuate treatment and assist in transdermal drug delivery for acne or other forms of treatment.


Just as the case with thermal effects, these mechanical effects may be provided at certain depths and zones within ROI 12. Applying energy at a certain level at a certain depth is used to cause certain mechanical effects at that level. In an exemplary embodiment, the more ultrasound energy 16 applied, the more mechanical effects are realized. Lower energy results in fewer effects. For example, applying energy at greater levels at certain locations within the tissues will result in greater mechanical effects such as streaming and cavitation which may be needed at those locations to achieve a certain result.


The amount of energy can vary at different levels and cause specific effects at one level while causing another effect at another level simultaneously. This treatment at different levels can create a combined treatment that works with or independently of the thermal effects described above. For example, providing ultrasound energy 16 at higher levels may be needed to cause sufficient cavitation and/or streaming at the depth of tissue where a pilosebaceous unit 14 is located and may be necessary to destroy bacteria within the pilosebaceous unit to prevent and cure acne.


As ultrasound energy 16 is being applied at sufficient levels to cause cavitation and/or streaming sufficient to destroy bacteria, lower energy levels could be applied at other area within ROI 12. Applying ultrasound energy 16 at lower levels at other depths and locations within ROI 12 may be needed to achieve other effects such as transdermal drug delivery. Transdermal drug delivery is achieved by using the mechanical effects to push medicines and other medicants into the tissue cells at ROI 12. Further, in an exemplary embodiment, the medicines can be contained within a coupling gel, cream, or other substance that is used to couple probe 26 or transducer to the patient's body at ROI 12.


An exemplary system 10 for a combined therapy profile treatment is provided and depicted in FIG. 4. In this exemplary embodiment, an ultrasound system comprising a probe 26, a control system 28, and a display system 30 is used to delivery energy such as ultrasound energy 16 to and monitor ROI 12. Other exemplary systems are disclosed in co-pending U.S. patent application Ser. No. 11/163,177 entitled “Method and System For Treating Acne and Sebaceous Glands” and U.S. patent application Ser. No. 10/950,112 entitled “Method and System For Combined Ultrasound Treatment,” both of which are hereby incorporated by reference.


An exemplary probe 26 is a transducer that emits ultrasound energy into ROI 12 to heat ROI 12 at specific depths and/or cause certain mechanical effects at specific depths. A coupling agent is used to couple probe 26 to a patient's body in one exemplary embodiment. In another exemplary embodiment, suction is used to attach probe 26 to the patient's body.


With additional reference to FIG. 5, an exemplary probe 26 is an annular array 32 with numerous transduction elements disposed within rings 34, 36, 38, 40, and 42. In this exemplary embodiment, each transduction element is configured to emit ultrasound energy 16 at different spatial and/or temporal levels which is capable of achieving different effects within ROI 12. In this exemplary embodiment, the transducer is divided into numerous rings 34-42 and each ring contains a separate transduction element. For example, the transduction element in ring 36 may be capable of producing ultrasound energy 16 that reaches 5 mm below the skin's surface while the transduction element in ring 38 may be capable of reaching 10 mm below the surface of the skin. In another exemplary embodiment, each ring may have multiple transduction elements that may or may not emit energy at the same level within a ring.


The elements within the rings may be capable of emitting energy reaching 15 mm, 20 mm, and 25 mm below the skin's surface respectively in this exemplary embodiment. In order to reach a certain depth within ROI 12, each transduction element 50 is constructed so that it may emit ultrasound energy 16 to reach this depth. System 10 can emit ultrasound energy at various frequency ranges. Certain exemplary ranges include about 0.10 MHz to 100 MHz or more. More specifically, exemplary frequencies include about 0.15 MHz and 0.2 MHz as lower frequencies and about 0.15 MHz to 100 MHz or more as higher frequencies. For example, in order to reach a depth of 0-15 mm, transduction element 50 has an operating power of about 10-100 watts and emits ultrasound energy 16 at a frequency of about 1-12 MHz. In order to reach a depth of about 0-20 mm, transduction element 50 has an operating power of about 20-200 watts and emits ultrasound energy at a frequency of about 1-9 MHz. Finally, to achieve a depth of about 0-25 mm, transduction element 50 has an operating power of about 1-120 watts and emits ultrasound energy 16 at a frequency of about 1-20 MHz.


With reference to FIG. 6 another exemplary annular array is show. In this exemplary embodiment, the annular array has three rings 44, 46, and 48 as shown. Each ring comprises a different transduction element 50 that is configured to emit ultrasound energy 16 with different temporal and/or spatial parameters. For example, ring 44 may be configured to emit ultrasound energy for a time period of 5 milliseconds, ring 46 may be configured emit ultrasound energy for 10 milliseconds, while ring 48 is configured to emit ultrasound energy for 15 milliseconds. In one exemplary embodiment, the time that ultrasound energy is emitted from each ring is controlled by control system 28. Emission of ultrasound energy 16 may be repeated at various times and depths to produce desired thermal and/or mechanical effects within ROI 12.


Energy such as ultrasound energy 16 can be emitted at various levels from each transduction element. These levels can be changed by varying the amount of energy emitted or the time it is emitted from system 10. For example, ultrasound energy 16 can be emitted at ablative or coagulative levels by being emitted at a high power for a short time or low power for a longer duration. The energy emission and time frames can be varied to achieve the desired level of energy emission. Moreover, the penetration depth of ultrasound energy 16 may be changed depending on which ring 46-48 it is emitted from. For example, as shown in FIG. 6, the ultrasound energy from ring 46 may only reach a shallow level compared to ultrasound energy from ring 48. Ultrasound energy 16 from ring 48 may be used to pre-heat ROI 12 before ultrasound energy 16 from ring 46 is emitted and thus create a profile as shown in FIG. 2.


In one exemplary embodiment, transduction elements 50 are configured to emit ultrasound energy at a focal depth of 3-4 millimeters. In other exemplary embodiments, a single transducer or probe with multiple elements 50 is configured to produce variable amounts of ultrasound energy. Specifically, a transducer can contain numerous elements 50 and each element 50 is constructed to emit ultrasound energy at different parameters. Certain exemplary parameters comprise the depth of ultrasound energy 16 penetrations, the power supplied to each element 50, the frequency of operation of each element 50, the focal strength or “F Number,” the depth or focal depth, and energy. In one exemplary embodiment, transduction elements 50 are arranged in probe 26 in a specific manner to create a controlled, predictable emission of ultrasound energy 16. For example, a transducer can be constructed by providing elements to generate a known, predetermined pattern of ultrasound energy within ROI 12.


In another exemplary embodiment, transduction elements 50 are arranged within probe 26 to create a “cloud” of lesions within ROI 12 wherein each lesion has a different size and depth. According to this exemplary embodiment, different elements 50 are selected for their emission times, frequencies, focal depth, focal strength (F-number), energies and other relevant parameters discussed herein. The elements 50 are placed on a device that moves and enables the lesions to be placed at different locations within ROI 12 depending on the location of the elements relative to ROI 12.


In another exemplary embodiment, varying these parameters from one element 50 to another element 50 contained within probe 26 may create a pseudo random emission pattern of ultrasound energy 16. The creation of a pseudo random emission of ultrasound energy 16 creates a wide spatial and/or temporal band of therapeutic efficacy.


A time-temperature profile for the method can be modeled and optimized with the aid of the thermal dose concept. The thermal dose, or t43, is the exposure time at 43° C. which causes an equivalent biological effect due to an arbitrary time-temperature heating profile. Typically an ablative lesion forms on the order of one second at 56° C., which corresponds to a thermal dose of one hundred and twenty minutes at 43° C. The same thermal dose corresponds to 50° C. for approximately one minute. Thus a non-ablative profile can contain high temperatures for very short times and/or lower temperatures for longer times or a combination of various time-temperature profiles. For example, temperatures as high as 56° C. for under one second or 46° C. for under fifteen minutes can be utilized. Such processes can be implemented in various exemplary embodiments, whereby one or more profiles may be combined into a single treatment.


In an exemplary embodiment the temperature is raised to a high level, such as approximately 50° C. or more and held for several seconds. In another exemplary embodiment, the temperature is raised to a high level, (for example greater than 50° C.), for under one second up to five seconds or more, and then turned off for under one second up to five seconds or more, and repeated to create a pulsed profile.


In another exemplary embodiment, the temperature is raised quickly to a high level (greater than 50° C.), and then dropped to a lower temperature (less than 50° C.), and then maintained at that temperature for a given time period such as one second up to several seconds or over a minute.


In another exemplary embodiment, the temperature is increased quickly to a high level (THIGH), whereby THIGH is greater than 40° C., and the power to the system is turned off, but turned on again once the temperature drops below a lower threshold, (TLOW), whereby TLOW is less than THIGH. Once the temperature reaches THIGH again power to the system is turned back off and this process is repeated, in effect acting like a thermostat.


In another exemplary embodiment, the temperature is raised quickly to a high level (TSTART), whereby TSTART is greater than 40° C. and then turned off, but turned on again before the temperature drops appreciably (i.e. by a few degrees) below TSTART, whereby the temperature may then increase a small amount (i.e. by a few degrees) over TSTART before the power is turned off again. In such an exemplary embodiment the temperature quickly reaches a starting point and then may be allowed to increase to a higher temperature yet still remain in a non-ablative or coagulative regime before the treatment is ended.


Besides annular array 32 depicted in FIG. 5, other transducers and probes 26 could be used and fall within the scope of the present invention. Other exemplary arrays include truncated annular array, a linear array, a linear phased array, or a two dimensional phased array. Certain exemplary transducers comprise transducers that are configured to move in any vertical or horizontal direction or transducer with an adjustable angular altitude. Any transducer arrangement configured to emit ultrasound energy 16 to depths within the tissue now known or developed in the future can be used and fall within the scope of the present invention.


The ultrasound energy 16 emitted can be emitted in various energy fields. The energy fields can be focused, defocused, and/or made substantially planar by the transducer to provide a plurality of different effects. Energy can be applied at one or more points in one or more C-planes or C-scans by automated or manual movement. For example, a substantially planar energy field can provide a heating and/or pretreatment effect, a focused energy field can provide a more concentrated source of heat or hyperthermal effect, and a non-focused energy field can provide diffused heating effects. It should be noted that the term “non-focused” as used throughout is meant to encompass energy that is unfocused or defocused.


An exemplary transducer emits ultrasound energy for imaging or treatment or a combination of both imaging and treatment. In an exemplary embodiment, the transducer is configured to emit ultrasound energy at specific depths in within ROI 12 as described above.


With reference to FIGS. 7A-7D, a transducer can comprise one or more transduction elements 50 configured for facilitating treatment. Transduction elements 50 can comprise a piezoelectrically active material, such as lead zirconante titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, a transducer can comprise any other materials configured for generating radiation and/or acoustical energy. The transducer can also comprise one or more matching and/or backing layers configured along with a transduction element(s) 50 such as coupled to the piezoelectrically active material. The transducer can also be configured with single or multiple damping elements along with transduction element 50.


In accordance with an exemplary embodiment, the transduction element 50 of the transducer can be configured to be uniform thereby having a narrowband resonance frequency distribution. In accordance with another exemplary embodiment, transduction element 50 can also be configured with a variable thickness, and/or as a multiple damped device, thereby having a wideband resonance frequency distribution. For example, transduction element 50 of the transducer can be configured to provide a center operating frequency of a lower range, for example from approximately 1 kHz to 3 MHz. Transduction element 50 can also be configured to provide a center operating frequency of a higher range, for example from approximately 3 to 100 MHz or more. In yet other exemplary embodiments, transduction element 50 is configured to emit ultrasound energy 16 at a frequency in the range of 1-15 MHz. In yet other exemplary embodiments, transduction element 50 is configured to emit ultrasound energy 16 at a frequency in the approximate range of 0.5 to 100 MHz, and in still yet other exemplary embodiments, transduction element 50 is configured to emit ultrasound energy at a frequency in the approximate range of 0.75 to 25 MHz. Other exemplary frequencies are in the approximate range of 0.75 MHz to 1.75 MHz. Harmonics and sub-harmonics can also be used in various embodiments of the present invention.


The transducer can be configured as a single broadband transducer excited with at least two or more frequencies such as 4 MHz and 7 MHz to provide an adequate output for raising the temperature and or causing the mechanical effects within the ROI to the desired level. The transducer can also be configured as two or more individual transducers, wherein each of the transducers comprises a separate transduction element 50.


Moreover, in an exemplary embodiment, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the energy field. For example, the transducer may also be configured with an electronic focusing array in combination with one or more transduction elements 50 to facilitate increased flexibility in treating the ROI. The array may be configured in a manner similar to the transducer. That is, the array can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, T1, T2, T3 . . . Tj. By the term “operated,” the electronic apertures of the array may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI 12.


Transduction elements 50 may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in FIG. 7A, transduction elements 50 are configured to be concave in order to provide focused energy for treatment of the ROI. Additional embodiments are disclosed in U.S. patent application Ser. No. 10/944,500, entitled “System and Method for Variable Depth Ultrasound Treatment”, and again incorporated herein by reference.


In one exemplary embodiment, transduction elements 50 are therapy line-focused single elements. Further, arrays 56, 58, 60, and 62 noted below may further comprise at least one imaging element 50 or a combination of imaging elements with treatment elements 50. In another exemplary embodiment, multiple-element, multiple-delay transducers 50 can be multiple-element, multiple-delay transducers perpendicular to those shown in FIGS. 7A and 7B, whereby such perpendicular disposes transducers are therapy, imaging, or dual-mode imaging-therapy elements.


In another exemplary embodiment, depicted in FIG. 7B, transduction elements 50 can be configured to be substantially flat in order to provide substantially uniform energy to ROI 12. While FIGS. 7A and 7B depict exemplary embodiments transduction elements 50 configured as concave and substantially flat, respectively, transduction elements 50 can be configured to be concave, convex, and/or substantially flat. In addition, transduction elements 50 can be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first transduction element 50 can be configured to be concave, while a second transduction element 50 can be configured to be substantially flat.


With reference to FIGS. 5, 6, and 7C, the transducer can also be configured as annular array 32 to provide planar, focused and/or defocused acoustical energy. The rings can be mechanically and electrically isolated into a set of individual elements, and can create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays, T1, T2, T3 . . . TN. An electronic focus can be suitably moved along various depth positions, and can enable variable strength or beam tightness, while an electronic defocus can have varying amounts of defocusing. In accordance with an exemplary embodiment, a lens and/or convex or a concave shaped annular array can also be provided to aid focusing or defocusing such that any time differential delays can be reduced. Movement of the annular array in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within ROI 12.


With reference to FIG. 7D, an exemplary transducer can also be configured as a spherically focused single element 51, an annular/multi-element 52, an annular element with imaging region(s) 54, a line-focused single element 56, a 1-D linear array 58, a 1-D curved (convex/concave) linear array 60, and/or 2-D array 62, with a mechanical focus, a convex lens focus, a concave lens focus, a compound/multiple lens focused, and/or planar array form to achieve focused, unfocused, or defocused sound fields for both imaging and/or therapy. Analogous to spherically focused single element 51 to be configured for multiple annuli 52 and/or imaging regions 54, an exemplary embodiment for the therapeutic line-focused single element 56, and 1-D and 2-D arrays 58, 60 and 62 is to dispose one or more imaging elements or imaging arrays in their aperture. In general a combination of imaging and therapy transducers or dual mode transducers can be used. In certain exemplary embodiments, spherical lens are used in treating acne and cylindrical lenses are used for treatment at ROI 12. Other lens shapes can still be used in other exemplary embodiments of the present invention.


With reference now to FIGS. 8A-8C, an exemplary transducer is suitably controlled and operated in various manners by control system 28. Control system 28 may be in a hand-held format. Certain exemplary control systems 28 are disclosed in co-pending U.S. patent application Ser. No. 11/738,682 which is incorporated by reference above. Further, exemplary system 28 also comprises display 30. Exemplary displays 30 are also disclosed in co-pending U.S. patent application Ser. No. 11/738,682.


In an exemplary embodiment, an exemplary control system 28 is configured for coordination and control of the entire treatment process. For example, control system 28 can suitably comprise power source components 66, sensing and monitoring components 68, cooling and coupling controls 70, and/or processing and control logic components 72. Control system 28 can be configured and optimized in a variety of ways with more or less subsystems and components.


For example, control system 28 can comprise one or more direct current (DC) power supplies 74 configured to provide electrical energy for the entire control system, including power required by a transducer electronic amplifier/driver. A DC current sense device 76 can also be provided to confirm the level of power going into amplifiers/drivers for safety and monitoring purposes.


The amplifiers/drivers 78 can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, the amplifiers/drivers can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer/oscillator 77 with related switching logic.


The power sourcing components can also include various filtering configurations 80. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver/beamformer 78 to increase the drive efficiency and effectiveness. Power detection components 82 may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components may be used to monitor the amount of power going to the probe.


Various sensing and monitoring components 84 may also be suitably implemented within the control system. For example, in accordance with an exemplary embodiment, the monitoring, sensing and interface control components 84 may be configured to operate with various motion detection systems implemented within the transducer to receive and process information such as acoustic or other spatial and/or temporal information from ROI 12. Sensing and monitoring components 84 can also include various controls, interfacing and switches 86 and/or power detectors. Such sensing and monitoring components can facilitate open-loop and/or closed-loop feedback systems within the system.


In an exemplary embodiment, the sensing and monitoring components comprise a sensor that is connected to an audio or visual alarm system to prevent overuse of the system. In this exemplary embodiment, the sensor senses the amount of energy transferred to the skin or the time that the system has be actively emitting energy. When a certain time or temperature threshold has been reached, the alarm sounds an audible alarm or causes a visual indicator to activate to alert the user that the threshold is reached. This prevents the user from overusing system. In an exemplary embodiment, the sensor could be operatively connected to the control system and force the control system to stop emitting ultrasound energy from the probe.


A cooling/coupling control system 88 may be provided to remove waste heat from an exemplary probe, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from the probe to the ROI. Such cooling/coupling control systems can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.


Additionally, an exemplary control system 28 can further comprise various system processor and digital control logic 90, such as one or more control or interfacing switches and associated components, including firmware and control software 92, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. The system software controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches can also be suitably configured to control operation. In an exemplary embodiment, control system 28 further comprises a mechanism and driver control 94.


With reference to FIG. 5C, an exemplary transducer is suitably controlled and operated in various manners by a hand-held format control system 96. An external battery charger 98 can be used with rechargeable-type batteries 97 or batteries can be single-use disposable types, such as AA-sized cells. Power converters 100 produce voltages suitable for powering a driver/feedback circuit with tuning network 102 driving a transducer coupled to the patient via one or more acoustic coupling caps 103. The cap can be composed of at least one of a solid media, semi-solid e.g. gelatinous media, and/or liquid media equivalent to an acoustic coupling agent (contained within a housing). Cap 103 is coupled to the patient with an acoustic coupling agent 104. Cap 103 and/or coupling agent 104 can be cooled, such as in a refrigerator, ice water, peltier cooling device, closed-loop cooling control or any other means of cooling. Cap 103 and/or coupling agent 104 can also be pre-heated, such as in an oven, hot water, resistive heating device, closed-loop heating or any other known means or mechanisms for heating.


In addition, a microcontroller and timing circuits 106 with associated software and algorithms provide control and user interfacing via display 30, oscillator 107, and other input/output controls 109 such as switches and audio devices. A storage element 108, such as an EEPROM, secure EEPROM, tamper-proof EEPROM, or similar device holds calibration and usage data. A motion mechanism with feedback 110 can be suitably controlled to scan the transducer, if desirable, in a line or two-dimensional pattern and/or with variable depth. Other feedback controls include a capacitive, acoustic, force, or other coupling detection means and/or limiting controls and thermal sensor 111. A combination of the secure EEPROM with at least one of coupling caps, transducer, thermal sensor, coupling detectors, or tuning network along with a plastic or other housing can comprise a disposable tip.


With reference again to FIG. 4, an exemplary system also comprises display 30 or a display system to provide images of ROI 12 in certain exemplary embodiments wherein ultrasound energy 16 is emitted from the transducer in a manner suitable for imaging. Display 30 can be any type of system that conveys images or information apart from images about the system 10 or ROI 12 to the user. Therefore, display 30 can be a computer monitor, television screen or it can simply be a simply type of indicator system such a liquid crystal display or light emitting diode display in various exemplary embodiments. Liquid crystal displays and light emitting diode displays are particularly useful when the system is a hand-held system.


Display 30 enables the user to facilitate localization of the treatment area and surrounding structures. After localization, delivery of ultrasound energy 16 at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect is provided. Before, during, and/or after therapy, i.e., before, during and/or after delivery of ultrasound energy 16, monitoring of the treatment area and surrounding structures can be conducted to further plan and assess the results and/or providing feedback to the control system and a system operator via display 30.


In accordance with another exemplary embodiment of the present invention, an exemplary monitoring method may comprise monitoring the temperature profile or other tissue parameters of ROI 12 such as attenuation, speed of sound, or mechanical properties such as stiffness and strain of the treatment region and suitably adjust the spatial and/or temporal characteristics and energy levels of the ultrasound energy emitted from probe 26. The results of such monitoring techniques may be indicated on the display system by means of one-, two-, or three-dimensional images of monitoring results, or may simply comprise a success or fail-type indicator, or combinations thereof. Additional treatment monitoring techniques may be based on one or more of temperature, video, profilometry, and/or stiffness or strain gauges or any other suitable sensing technique.


In certain exemplary embodiments, system 10 is equipped with certain features to aid the user. One feature is a disposable tip that covers probe 26 during use. The disposable tip enables ultrasound energy 26 to pass through the tip and contact the patient. But, the disposable tip can be removed from probe 26 after use and replaced with a new disposable tip to prevent the spread of germs from one patient to another that might reside on the probe after contact with a patient's skin. Different size disposable tips can be used and fall within the scope of the present invention.


Present exemplary embodiments may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, other exemplary embodiments may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, exemplary embodiments may be practiced in any number of medical contexts and that the exemplary embodiments relating to a system as described herein are merely indicative of exemplary applications for the disclosed subject matter. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of the present disclosure may be suitably applied to other applications, such as other medical or industrial applications.

Claims
  • 1. A method of treating tissue at multiple depths within a region of interest comprising: coupling a device comprising an ultrasound transducer configured to emit and focus a first beam of energy and a second beam of energy into a region of interest comprising a skin surface and subcutaneous tissue;focusing the first beam of energy to the skin surface of the region of interest;focusing the second beam of energy to a location within the subcutaneous tissue in the region of interest;stimulating a first therapeutic effect to tissue in the skin surface with the first beam of energy; andstimulating a second therapeutic effect in the subcutaneous tissue with the second beam of energy;wherein the first beam of energy and the second beam of energy each have unique spatial and temporal properties andwherein the first therapeutic effect and the second therapeutic effect are different.
  • 2. The method according to claim 1 wherein the energy is ultrasound energy.
  • 3. The method according to claim 2 wherein the first beam of ultrasound energy and the second beam of ultrasound energy are applied simultaneously.
  • 4. A method of treating tissue with ultrasound energy comprising: applying a coupling agent to a patient's body;coupling an ultrasound probe configured to emit ultrasound enemy to a region of interest comprising tissue;applying a first application of ultrasound energy at one location within the region of interest with defined spatial and temporal characteristics;applying, a second, application of ultrasound energy at a second location within the region of interest with different defined spatial and temporal characteristics than the first application of ultrasound energy; andproviding a combined therapeutic energy profile in the region of interest, which is different than either a, first time-temperature profile created by the first application of ultrasound energy or a second time-temperature profile created by the second application of ultrasound energy.
  • 5. The method according to claim 4 wherein the first application of ultrasound energy and the second application of ultrasound energy are applied at targets that are in a linear relationship to one another.
  • 6. The method according claim 4, wherein the first application of ultrasound energy and the second application of ultrasound energy are applied simultaneously to the region of interest.
  • 7. A method of treating tissue with ultrasound energy comprising: coupling a transducer probe to a region of interest comprising tissue, wherein the transducer probe comprises different transduction elements configured for producing ultrasound energy for different time lengths and with a different geometric pattern;applying a first application of ultrasound energy at one location, within a region of interest with defined spatial and temporal characteristics,applying a second application of ultrasound energy at a second another location within the region of interest with different defined spatial and temporal characteristics than the first application of ultrasound energy; andproviding a combined therapeutic energy profile different than either an ablative temperature profile created by the first application of ultrasound energy or a non ablative temperature profile created by the second application of ultrasound energy.
  • 8. The method according to claim 7 wherein the first application of ultrasound energy and the second application of ultrasound energy are applied at targets that are in a linear relationship to one another within the region of interest.
  • 9. The method according claim 7, wherein the first application of ultrasound energy and the second application of ultrasound energy are applied simultaneously to the region of interest.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to and the benefit of U.S. Provisional Patent Application No. 60/916,475 filed May 7, 2007 entitled “Method and System for Combined Energy Profile,” wherein such provisional application is hereby incorporated in its entirety, by reference and this application is a continuation-in-part of U.S. Patent Application assigned Ser. No. 10/944,500 entitled System and Method For Variable Depth Ultrasound Treatment that was filed on Sep. 16, 2004, wherein such application is incorporated in its entirety by reference.

US Referenced Citations (803)
Number Name Date Kind
2427348 Bond et al. Sep 1947 A
3913386 Saglio Oct 1975 A
3965455 Hurwitz Jun 1976 A
3992925 Perilhou Nov 1976 A
4039312 Patru Aug 1977 A
4059098 Murdock Nov 1977 A
4101795 Fukumoto Jul 1978 A
4166967 Benes et al. Sep 1979 A
4211948 Brisken et al. Jul 1980 A
4211949 Brisken et al. Jul 1980 A
4213344 Rose Jul 1980 A
4276491 Daniel Jun 1981 A
4315514 Drewes et al. Feb 1982 A
4325381 Glenn Apr 1982 A
4343301 Indech Aug 1982 A
4372296 Fahim Feb 1983 A
4379145 Masuho et al. Apr 1983 A
4381007 Doss Apr 1983 A
4381787 Hottinger May 1983 A
4397314 Vaguine Aug 1983 A
4409839 Taenzer Oct 1983 A
4431008 Wanner et al. Feb 1984 A
4441486 Pounds Apr 1984 A
4452084 Taenzer Jun 1984 A
4484569 Driller Nov 1984 A
4507582 Glenn Mar 1985 A
4513749 Kino et al. Apr 1985 A
4513750 Heyman et al. Apr 1985 A
4527550 Ruggera et al. Jul 1985 A
4528979 Marchenko Jul 1985 A
4534221 Fife et al. Aug 1985 A
4566459 Umemura et al. Jan 1986 A
4567895 Putzke Feb 1986 A
4586512 Do-Huu et al. May 1986 A
4601296 Yerushalmi Jul 1986 A
4620546 Aida et al. Nov 1986 A
4637256 Sugiyama et al. Jan 1987 A
4646756 Watmough Mar 1987 A
4663358 Hyon May 1987 A
4668516 Duraffourd et al. May 1987 A
4672591 Breimesser et al. Jun 1987 A
4680499 Umemura et al. Jul 1987 A
4697588 Reichenberger Oct 1987 A
4754760 Fukukita et al. Jul 1988 A
4757820 Itoh Jul 1988 A
4771205 Mequio Sep 1988 A
4801459 Liburdy Jan 1989 A
4803625 Fu et al. Feb 1989 A
4807633 Fry Feb 1989 A
4817615 Fukukita et al. Apr 1989 A
4858613 Fry et al. Aug 1989 A
4860732 Hasegawa et al. Aug 1989 A
4865041 Hassler Sep 1989 A
4865042 Umemura Sep 1989 A
4867169 Machida Sep 1989 A
4874562 Hyon Oct 1989 A
4875487 Seppi Oct 1989 A
4891043 Zeimer et al. Jan 1990 A
4893624 Lele Jan 1990 A
4896673 Rose Jan 1990 A
4900540 Ryan et al. Feb 1990 A
4901729 Saitoh et al. Feb 1990 A
4917096 Englehart et al. Apr 1990 A
4973096 Jaworski Apr 1990 A
4932414 Coleman et al. Jun 1990 A
4938216 Lele Jul 1990 A
4938217 Lele Jul 1990 A
4947046 Kawabata et al. Aug 1990 A
4951653 Fry et al. Aug 1990 A
4955365 Fry et al. Sep 1990 A
4958626 Nambu Sep 1990 A
4976709 Sand Dec 1990 A
4979501 Valchanov Dec 1990 A
4992989 Watanabe et al. Feb 1991 A
5012797 Liang May 1991 A
5018508 Fry et al. May 1991 A
5030874 Saito et al. Jul 1991 A
5036855 Fry et al. Aug 1991 A
5040537 Katakura Aug 1991 A
5054310 Flynn Oct 1991 A
5054470 Fry et al. Oct 1991 A
5070879 Herres Dec 1991 A
5088495 Miyagawa Feb 1992 A
5115814 Griffith May 1992 A
5117832 Sanghvi et al. Jun 1992 A
5123418 Saurel Jun 1992 A
5143063 Fellner Sep 1992 A
5143074 Dory Sep 1992 A
5149319 Unger Sep 1992 A
5150711 Dory Sep 1992 A
5150714 Green Sep 1992 A
5152294 Mochizuki et al. Oct 1992 A
5156144 Iwasaki et al. Oct 1992 A
5158536 Sekins Oct 1992 A
5159931 Pini Nov 1992 A
5163421 Bernstein et al. Nov 1992 A
5163436 Saitoh et al. Nov 1992 A
5190518 Takasu Mar 1993 A
5190766 Ishihara Mar 1993 A
5191880 McLeod et al. Mar 1993 A
5205287 Erbel et al. Apr 1993 A
5209720 Unger May 1993 A
5212671 Fujii et al. May 1993 A
5215680 D Arrigo Jun 1993 A
5224467 Oku Jul 1993 A
5230334 Klopotek Jul 1993 A
5230338 Allen et al. Jul 1993 A
5247924 Suzuki et al. Sep 1993 A
5255681 Ishimura et al. Oct 1993 A
5257970 Dougherty Nov 1993 A
5265614 Hayakawa Nov 1993 A
5267985 Shimada et al. Dec 1993 A
5269297 Weng Dec 1993 A
5282797 Chess Feb 1994 A
5295484 Marcus Mar 1994 A
5295486 Wollschlaeger et al. Mar 1994 A
5304169 Sand Apr 1994 A
5305756 Entrekin et al. Apr 1994 A
5321520 Inga et al. Jun 1994 A
5323779 Hardy et al. Jun 1994 A
5327895 Hashimoto et al. Jul 1994 A
5348016 Unger et al. Sep 1994 A
5360268 Hayashi Nov 1994 A
5370121 Reichenberger et al. Dec 1994 A
5371483 Bhardwaj Dec 1994 A
5375602 Lancee et al. Dec 1994 A
5380280 Peterson Jan 1995 A
5380519 Schneider et al. Jan 1995 A
5391140 Schaetzle Feb 1995 A
5391197 Burdette et al. Feb 1995 A
5392259 Bolorforosh Feb 1995 A
5396143 Seyed-Bolorforosh et al. Mar 1995 A
5398689 Connor et al. Mar 1995 A
5406503 Williams, Jr. et al. Apr 1995 A
5417216 Tanaka May 1995 A
5419327 Rohwedder et al. May 1995 A
5423220 Finsterwald et al. Jun 1995 A
5435311 Umemura Jul 1995 A
5438998 Hanafy Aug 1995 A
5458596 Lax et al. Oct 1995 A
5460179 Okunuki et al. Oct 1995 A
5460595 Hall et al. Oct 1995 A
5469854 Unger et al. Nov 1995 A
5471988 Fujio Dec 1995 A
5487388 Rello et al. Jan 1996 A
5492126 Hennige et al. Feb 1996 A
5496256 Bock Mar 1996 A
5501655 Rolt et al. Mar 1996 A
5503152 Oakley et al. Apr 1996 A
5503320 Webster et al. Apr 1996 A
5507790 Weiss Apr 1996 A
5520188 Hennige et al. May 1996 A
5522869 Burdette Jun 1996 A
5523058 Umemura et al. Jun 1996 A
5524620 Rosenschein Jun 1996 A
5524624 Tepper Jun 1996 A
5524625 Okazaki et al. Jun 1996 A
5526624 Berg Jun 1996 A
5526812 Dumoulin et al. Jun 1996 A
5526814 Cline et al. Jun 1996 A
5526815 Granz et al. Jun 1996 A
5529070 Augustine et al. Jun 1996 A
5540235 Wilson Jul 1996 A
5558092 Unger et al. Sep 1996 A
5560362 Sliwa et al. Oct 1996 A
5575291 Hayakawa Nov 1996 A
5575807 Faller Nov 1996 A
5577502 Darrow et al. Nov 1996 A
5577507 Snyder et al. Nov 1996 A
5577991 Akui et al. Nov 1996 A
5580575 Unger et al. Dec 1996 A
5601526 Chapelon et al. Feb 1997 A
5603323 Pflugrath et al. Feb 1997 A
5609562 Kaali Mar 1997 A
5615091 Palatnik Mar 1997 A
5617858 Taverna et al. Apr 1997 A
5618275 Bock Apr 1997 A
5620479 Diederich Apr 1997 A
5622175 Sudol et al. Apr 1997 A
5638819 Manwaring et al. Jun 1997 A
5643179 Fujimoto Jul 1997 A
5644085 Lorraine et al. Jul 1997 A
5647373 Paltieli Jul 1997 A
5655535 Friemel et al. Aug 1997 A
5655538 Lorraine Aug 1997 A
5657760 Ying Aug 1997 A
5658328 Johnson Aug 1997 A
5660836 Knowlton Aug 1997 A
5662116 Kondo et al. Sep 1997 A
5665053 Jacobs Sep 1997 A
5665141 Vago Sep 1997 A
5671746 Dreschel et al. Sep 1997 A
5676692 Sanghvi et al. Oct 1997 A
5685820 Riek et al. Nov 1997 A
5687737 Branham et al. Nov 1997 A
5690608 Watanabe Nov 1997 A
5694936 Fujimoto Dec 1997 A
5697897 Buchholtz Dec 1997 A
5701900 Shehada et al. Dec 1997 A
5704361 Seward et al. Jan 1998 A
5706252 Le Verrier et al. Jan 1998 A
5706564 Rhyne Jan 1998 A
5715823 Wood et al. Feb 1998 A
5720287 Chapelon et al. Feb 1998 A
5722411 Suzuki Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5743863 Chapelon Apr 1998 A
5746005 Steinberg May 1998 A
5746762 Bass May 1998 A
5748767 Raab May 1998 A
5749364 Sliwa et al. May 1998 A
5755228 Wilson et al. May 1998 A
5755753 Knowlton May 1998 A
5762066 Law et al. Jun 1998 A
5763886 Schulte Jun 1998 A
5769790 Watkins et al. Jun 1998 A
5779644 Eberle et al. Jul 1998 A
5792058 Lee et al. Aug 1998 A
5795297 Daigle Aug 1998 A
5795311 Wess Aug 1998 A
5810009 Mine et al. Sep 1998 A
5810888 Fenn Sep 1998 A
5814599 Mitragotri et al. Sep 1998 A
5817013 Ginn et al. Oct 1998 A
5817021 Reichenberger Oct 1998 A
5820564 Slayton et al. Oct 1998 A
5823962 Schaetzle Oct 1998 A
5827204 Grandia et al. Oct 1998 A
5840032 Hatfield et al. Nov 1998 A
5844140 Seale Dec 1998 A
5853367 Chalek et al. Dec 1998 A
5869751 Bonin Feb 1999 A
5871524 Knowlton Feb 1999 A
5873902 Sanghvi et al. Feb 1999 A
5876431 Spehr et al. Mar 1999 A
5879303 Averkiou et al. Mar 1999 A
5882557 Hayakawa Mar 1999 A
5891034 Bucholz Apr 1999 A
5899861 Friemel et al. May 1999 A
5904659 Duarte et al. May 1999 A
5919219 Knowlton Jul 1999 A
5923099 Bilir Jul 1999 A
5924989 Polz Jul 1999 A
5928169 Schatzle et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5938606 Bonnefous Aug 1999 A
5938612 Kline-Schoder et al. Aug 1999 A
5948011 Knowlton Sep 1999 A
5957844 Dekel Sep 1999 A
5957882 Nita et al. Sep 1999 A
5957941 Ream Sep 1999 A
5967980 Ferre et al. Oct 1999 A
5968034 Fullmer et al. Oct 1999 A
5971949 Levin Oct 1999 A
5977538 Unger et al. Nov 1999 A
5984882 Rosenschein Nov 1999 A
5990598 Sudol et al. Nov 1999 A
5997471 Gumb et al. Dec 1999 A
5997497 Nita et al. Dec 1999 A
5999843 Anbar Dec 1999 A
6004262 Putz et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6013032 Savord Jan 2000 A
6016255 Bolan et al. Jan 2000 A
6019724 Gronningsaeter et al. Feb 2000 A
6022308 Williams Feb 2000 A
6036646 Barthe et al. Mar 2000 A
6039048 Silberg Mar 2000 A
6039689 Lizzi Mar 2000 A
6042556 Beach et al. Mar 2000 A
6049159 Barthe et al. Apr 2000 A
6050943 Slayton et al. Apr 2000 A
6059727 Fowlkes May 2000 A
6071239 Cribbs et al. Jun 2000 A
6080108 Dunham Jun 2000 A
6083148 Williams Jul 2000 A
6086535 Ishibashi Jul 2000 A
6086580 Mordon et al. Jul 2000 A
6090054 Tagishi Jul 2000 A
6093883 Sanghvi et al. Jul 2000 A
6101407 Groezinger Aug 2000 A
6106469 Suzuki et al. Aug 2000 A
6113558 Rosenschein Sep 2000 A
6113559 Klopotek Sep 2000 A
6120452 Barthe et al. Sep 2000 A
6123081 Durette Sep 2000 A
6126619 Peterson et al. Oct 2000 A
6135971 Hutchinson et al. Oct 2000 A
6139499 Wilk Oct 2000 A
6159150 Yale et al. Dec 2000 A
6171244 Finger et al. Jan 2001 B1
6176840 Nishimura Jan 2001 B1
6183426 Akisada et al. Feb 2001 B1
6183502 Takeuchi Feb 2001 B1
6183773 Anderson Feb 2001 B1
6190323 Dias et al. Feb 2001 B1
6190336 Duarte et al. Feb 2001 B1
6193658 Wendelken et al. Feb 2001 B1
6210327 Brackett et al. Apr 2001 B1
6213948 Barthe et al. Apr 2001 B1
6216029 Paltieli Apr 2001 B1
6233476 Strommer et al. May 2001 B1
6234990 Rowe et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6246898 Vesely et al. Jun 2001 B1
6251088 Kaufman et al. Jun 2001 B1
6268405 Yao Jul 2001 B1
6273864 Duarte et al. Aug 2001 B1
6280402 Ishibashi et al. Aug 2001 B1
6287257 Matichuk Sep 2001 B1
6296619 Brisken Oct 2001 B1
6301989 Brown et al. Oct 2001 B1
6309355 Cain et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6315741 Martin et al. Nov 2001 B1
6322509 Pan et al. Nov 2001 B1
6322532 D'Sa Nov 2001 B1
6325540 Lounsberry et al. Dec 2001 B1
6325758 Carol et al. Dec 2001 B1
6325769 Klopotek Dec 2001 B1
6325798 Edwards et al. Dec 2001 B1
6338716 Hossack et al. Jan 2002 B1
6350276 Knowlton Feb 2002 B1
6356780 Licato et al. Mar 2002 B1
6361531 Hissong Mar 2002 B1
6370411 Osadchy et al. Apr 2002 B1
6375672 Aksan et al. Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6390982 Bova et al. May 2002 B1
6405090 Knowlton Jun 2002 B1
6409720 Hissong et al. Jun 2002 B1
6413216 Cain et al. Jul 2002 B1
6413253 Koop et al. Jul 2002 B1
6413254 Hissong et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6423007 Lizzi et al. Jul 2002 B2
6425865 Salcudean et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6428477 Mason Aug 2002 B1
6428532 Doukas et al. Aug 2002 B1
6430446 Knowlton Aug 2002 B1
6432057 Mazess et al. Aug 2002 B1
6432067 Martin et al. Aug 2002 B1
6432101 Weber et al. Aug 2002 B1
6436061 Costantino Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440071 Slayton et al. Aug 2002 B1
6443914 Costantino Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6488626 Lizzi et al. Dec 2002 B1
6491657 Rowe Dec 2002 B2
6500121 Slayton et al. Dec 2002 B1
6500141 Irion et al. Dec 2002 B1
6508774 Acker Jan 2003 B1
6511427 Sliwa, Jr. et al. Jan 2003 B1
6511428 Azuma Jan 2003 B1
6514244 Pope et al. Feb 2003 B2
6517484 Wilk et al. Feb 2003 B1
6524250 Weber Feb 2003 B1
6540679 Slayton et al. Apr 2003 B2
6540685 Rhoads et al. Apr 2003 B1
6540700 Fujimoto et al. Apr 2003 B1
6554771 Buil et al. Apr 2003 B1
6569099 Babaev May 2003 B1
6569108 Sarvazyan et al. May 2003 B2
6572552 Fukukita Jun 2003 B2
6575956 Brisken et al. Jun 2003 B1
6595934 Hissong et al. Jul 2003 B1
6599256 Acker Jul 2003 B1
6607498 Eshel Aug 2003 B2
6618620 Freundlich et al. Sep 2003 B1
6623430 Slayton et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6663627 He et al. Oct 2003 B2
6645162 Friedman et al. Nov 2003 B2
6662054 Kreindel Dec 2003 B2
6665806 Shimizu Dec 2003 B1
6666835 Martin Dec 2003 B2
6669638 Miller et al. Dec 2003 B1
6685640 Fry et al. Feb 2004 B1
6692450 Coleman Feb 2004 B1
6699237 Weber Mar 2004 B2
6716184 Vaezy et al. Apr 2004 B2
6719449 Laughlin Apr 2004 B1
6719694 Weng et al. Apr 2004 B2
6726627 Lizzi et al. Apr 2004 B1
6733449 Krishnamurthy et al. May 2004 B1
6749624 Knowlton Jun 2004 B2
6773409 Truckai et al. Aug 2004 B2
6775404 Pagoulatos et al. Aug 2004 B1
6790187 Thompson et al. Sep 2004 B2
6824516 Batten et al. Nov 2004 B2
6835940 Morikawa et al. Dec 2004 B2
6846290 Lizzi et al. Jan 2005 B2
6875176 Mourad Apr 2005 B2
6887239 Elstrom et al. May 2005 B2
6889089 Behl May 2005 B2
6896657 Willis May 2005 B2
6902536 Manna Jun 2005 B2
6905466 Salgo Jun 2005 B2
6918907 Kelly Jul 2005 B2
6920883 Bessette Jul 2005 B2
6921371 Wilson Jul 2005 B2
6932771 Whitmore Aug 2005 B2
6932814 Wood Aug 2005 B2
6936044 McDaniel Aug 2005 B2
6936046 Hissong et al. Aug 2005 B2
6945937 Culp et al. Sep 2005 B2
6948843 Laugharn et al. Sep 2005 B2
6953941 Nakano et al. Oct 2005 B2
6958043 Hissong Oct 2005 B2
6974417 Lockwood Dec 2005 B2
6976492 Ingle Dec 2005 B2
6992305 Maezawa et al. Jan 2006 B2
6997923 Anderson et al. Feb 2006 B2
7006874 Knowlton Feb 2006 B2
7020528 Neev Mar 2006 B2
7022089 Ooba Apr 2006 B2
7058440 Heuscher et al. Jun 2006 B2
7063666 Weng et al. Jun 2006 B2
7070565 Vaezy et al. Jul 2006 B2
7074218 Washington et al. Jul 2006 B2
7094252 Koop Aug 2006 B2
7108663 Talish et al. Sep 2006 B2
7115123 Knowlton Oct 2006 B2
7122029 Koop et al. Oct 2006 B2
7142905 Slayton et al. Nov 2006 B2
7165451 Brooks et al. Jan 2007 B1
7179238 Hissong Feb 2007 B2
7189230 Knowlton Mar 2007 B2
7229411 Slayton et al. Jun 2007 B2
7235592 Muratoglu Jun 2007 B2
7258674 Cribbs et al. Aug 2007 B2
7273459 Desilets Sep 2007 B2
7294125 Phalen et al. Nov 2007 B2
7297117 Trucco et al. Nov 2007 B2
7303555 Makin et al. Dec 2007 B2
7327071 Nishiyama et al. Feb 2008 B2
7331951 Eshel et al. Feb 2008 B2
7332985 Larson, III et al. Feb 2008 B2
7347855 Eshel Mar 2008 B2
RE40403 Cho et al. Jun 2008 E
7393325 Barthe et al. Jul 2008 B2
7398116 Edwards Jul 2008 B2
7399279 Abend et al. Jul 2008 B2
7510536 Foley et al. Mar 2009 B2
7530356 Slayton May 2009 B2
7530958 Slayton May 2009 B2
7571336 Barthe Aug 2009 B2
7601120 Moilanen et al. Oct 2009 B2
7615015 Coleman Nov 2009 B2
7615016 Barthe Nov 2009 B2
7686763 Vaezy et al. Mar 2010 B2
7695437 Quistgaard et al. Apr 2010 B2
7758524 Barthe Jul 2010 B2
7789841 Huckle et al. Sep 2010 B2
7824348 Barthe et al. Nov 2010 B2
7846096 Mast et al. Dec 2010 B2
7857773 Desilets et al. Dec 2010 B2
7875023 Eshel et al. Jan 2011 B2
7914453 Slayton et al. Mar 2011 B2
7914469 Torbati Mar 2011 B2
7931611 Novak et al. Apr 2011 B2
7955281 Pedersen et al. Jun 2011 B2
7967839 Flock et al. Jun 2011 B2
8057389 Barthe et al. Nov 2011 B2
8057465 Sliwa, Jr. et al. Nov 2011 B2
8066641 Barthe et al. Nov 2011 B2
8123707 Huckle et al. Feb 2012 B2
8128618 Gliklich et al. Mar 2012 B2
8133180 Slayton et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8197409 Foley et al. Jun 2012 B2
8206299 Foley et al. Jun 2012 B2
8211017 Foley et al. Jul 2012 B2
8262591 Pedersen et al. Sep 2012 B2
8273037 Kreindel et al. Sep 2012 B2
8282554 Makin et al. Oct 2012 B2
8333700 Barthe et al. Dec 2012 B1
8366622 Slayton et al. Feb 2013 B2
8409097 Slayton et al. Apr 2013 B2
8444562 Barthe et al. May 2013 B2
8480585 Slayton et al. Jul 2013 B2
8506486 Slayton et al. Aug 2013 B2
8523775 Barthe et al. Sep 2013 B2
8535228 Slayton et al. Sep 2013 B2
8585618 Hunziker et al. Nov 2013 B2
8636665 Slayton et al. Jan 2014 B2
8641622 Barthe et al. Feb 2014 B2
8663112 Slayton et al. Mar 2014 B2
8672848 Slayton et al. Mar 2014 B2
8690778 Slayton et al. Apr 2014 B2
8690779 Slayton et al. Apr 2014 B2
8690780 Slayton et al. Apr 2014 B2
8708935 Barthe et al. Apr 2014 B2
8715186 Slayton et al. May 2014 B2
8726781 Eckhoff et al. May 2014 B2
20010009997 Pope et al. Jul 2001 A1
20010009999 Kaufman et al. Jul 2001 A1
20010014780 Martin et al. Aug 2001 A1
20010014819 Ingle et al. Aug 2001 A1
20010031922 Weng et al. Oct 2001 A1
20010039380 Larson et al. Nov 2001 A1
20010041880 Brisken Nov 2001 A1
20020000763 Jones Jan 2002 A1
20020002345 Marlinghaus Jan 2002 A1
20020040199 Klopotek Apr 2002 A1
20020040442 Ishidera Apr 2002 A1
20020052550 Madsen et al. May 2002 A1
20020055702 Atala May 2002 A1
20020062077 Emmenegger et al. May 2002 A1
20020062142 Knowlton May 2002 A1
20020072691 Thompson et al. Jun 2002 A1
20020082528 Friedman et al. Jun 2002 A1
20020082529 Suorsa et al. Jun 2002 A1
20020082589 Friedman et al. Jun 2002 A1
20020087080 Slayton et al. Jul 2002 A1
20020095143 Key Jul 2002 A1
20020099094 Anderson Jul 2002 A1
20020115917 Honda et al. Aug 2002 A1
20020128648 Weber Sep 2002 A1
20020143252 Dunne et al. Oct 2002 A1
20020156400 Babaev Oct 2002 A1
20020161357 Anderson et al. Oct 2002 A1
20020165529 Danek Nov 2002 A1
20020168049 Schriever et al. Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169442 Neev Nov 2002 A1
20020173721 Grunwald et al. Nov 2002 A1
20020193784 Mchale et al. Dec 2002 A1
20020193831 Smith Dec 2002 A1
20030009153 Brisken et al. Jan 2003 A1
20030014039 Barzell et al. Jan 2003 A1
20030018255 Martin Jan 2003 A1
20030028111 Vaezy et al. Feb 2003 A1
20030028113 Gilbert et al. Feb 2003 A1
20030032900 Ella Feb 2003 A1
20030036706 Slayton et al. Feb 2003 A1
20030040739 Koop Feb 2003 A1
20030050678 Sierra Mar 2003 A1
20030055417 Truckai et al. Mar 2003 A1
20030060736 Martin et al. Mar 2003 A1
20030065313 Koop Apr 2003 A1
20030074023 Kaplan Apr 2003 A1
20030083536 Eshel et al. May 2003 A1
20030092988 Makin May 2003 A1
20030097071 Halmann et al. May 2003 A1
20030099383 Lefebvre May 2003 A1
20030125629 Ustuner Jul 2003 A1
20030139790 Ingle et al. Jul 2003 A1
20030171678 Batten et al. Sep 2003 A1
20030171701 Babaev Sep 2003 A1
20030176790 Slayton Sep 2003 A1
20030191396 Sanghvi et al. Oct 2003 A1
20030200481 Stanley Oct 2003 A1
20030212129 Liu et al. Nov 2003 A1
20030212351 Hissong et al. Nov 2003 A1
20030212393 Knowlton et al. Nov 2003 A1
20030216795 Harth et al. Nov 2003 A1
20030220536 Hissong Nov 2003 A1
20030220585 Hissong Nov 2003 A1
20030229331 Brisken et al. Dec 2003 A1
20030236487 Knowlton Dec 2003 A1
20040000316 Knowlton Jan 2004 A1
20040001809 Brisken Jan 2004 A1
20040002705 Knowlton Jan 2004 A1
20040010222 Nunomura et al. Jan 2004 A1
20040015106 Coleman Jan 2004 A1
20040015559 Goldstein Jan 2004 A1
20040030227 Littrup et al. Feb 2004 A1
20040039312 Hillstead et al. Feb 2004 A1
20040039418 Elstrom et al. Feb 2004 A1
20040041563 Lewin et al. Mar 2004 A1
20040042168 Yang et al. Mar 2004 A1
20040044375 Diederich et al. Mar 2004 A1
20040049134 Tosaya et al. Mar 2004 A1
20040049734 Simske Mar 2004 A1
20040059266 Fry et al. Mar 2004 A1
20040068186 Ishida et al. Apr 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040073113 Salgo et al. Apr 2004 A1
20040073115 Horzewski et al. Apr 2004 A1
20040073116 Smith Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082857 Schonenberger et al. Apr 2004 A1
20040082859 Schaer Apr 2004 A1
20040102697 Evron May 2004 A1
20040122323 Vortman et al. Jun 2004 A1
20040122493 Ishibashi et al. Jun 2004 A1
20040143297 Ramsey Jul 2004 A1
20040152982 Hwang et al. Aug 2004 A1
20040158150 Rabiner et al. Aug 2004 A1
20040186535 Knowlton Sep 2004 A1
20040189155 Funakubo Sep 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040217675 Desilets Nov 2004 A1
20040249318 Tanaka Dec 2004 A1
20040254620 Lacoste et al. Dec 2004 A1
20040267252 Washington et al. Dec 2004 A1
20050033201 Takahashi Feb 2005 A1
20050033316 Kertz Feb 2005 A1
20050038340 Vaezy et al. Feb 2005 A1
20050055073 Weber Mar 2005 A1
20050061834 Garcia et al. Mar 2005 A1
20050070961 Maki et al. Mar 2005 A1
20050074407 Smith Apr 2005 A1
20050080469 Larson et al. Apr 2005 A1
20050091770 Mourad et al. May 2005 A1
20050096542 Weng et al. May 2005 A1
20050104690 Larson, III et al. May 2005 A1
20050113689 Gritzky May 2005 A1
20050134314 Prather et al. Jun 2005 A1
20050137656 Malak Jun 2005 A1
20050143677 Young et al. Jun 2005 A1
20050154313 Desilets Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050154332 Zanelli Jul 2005 A1
20050154431 Quistgaard Jul 2005 A1
20050187495 Quistgaard et al. Aug 2005 A1
20050191252 Mitsui Sep 2005 A1
20050193451 Quistgaard et al. Sep 2005 A1
20050197681 Barolet et al. Sep 2005 A1
20050228281 Nefos Oct 2005 A1
20050240170 Zhang et al. Oct 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050256406 Barthe et al. Nov 2005 A1
20050261584 Eshel Nov 2005 A1
20050261585 Makin et al. Nov 2005 A1
20050267454 Hissong et al. Dec 2005 A1
20050288748 Li et al. Dec 2005 A1
20060004306 Altshuler Jan 2006 A1
20060020260 Dover et al. Jan 2006 A1
20060025756 Francischelli Feb 2006 A1
20060042201 Curry Mar 2006 A1
20060058664 Barthe Mar 2006 A1
20060058707 Barthe et al. Mar 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060074309 Bonnefous Apr 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060074314 Slayton et al. Apr 2006 A1
20060074355 Slayton et al. Apr 2006 A1
20060079816 Barthe et al. Apr 2006 A1
20060079868 Makin et al. Apr 2006 A1
20060084891 Barthe et al. Apr 2006 A1
20060089632 Barthe et al. Apr 2006 A1
20060089688 Panescu Apr 2006 A1
20060094988 Tosaya et al. May 2006 A1
20060111744 Makin et al. May 2006 A1
20060116583 Ogasawara et al. Jun 2006 A1
20060116671 Slayton et al. Jun 2006 A1
20060122508 Slayton Jun 2006 A1
20060122509 Slayton et al. Jun 2006 A1
20060161062 Arditi et al. Jul 2006 A1
20060184069 Vaitekunas Aug 2006 A1
20060184071 Klopotek Aug 2006 A1
20060189972 Grossman Aug 2006 A1
20060206105 Chopra et al. Sep 2006 A1
20060229514 Wiener Oct 2006 A1
20060241440 Eshel Oct 2006 A1
20060241442 Barthe et al. Oct 2006 A1
20060241470 Novak et al. Oct 2006 A1
20060250046 Koizumi et al. Nov 2006 A1
20060282691 Barthe et al. Dec 2006 A1
20060291710 Wang et al. Dec 2006 A1
20070032784 Gliklich et al. Feb 2007 A1
20070035201 Desilets Feb 2007 A1
20070055154 Torbati Mar 2007 A1
20070055155 Owen et al. Mar 2007 A1
20070055156 Desilets et al. Mar 2007 A1
20070065420 Johnson Mar 2007 A1
20070083120 Cain et al. Apr 2007 A1
20070087060 Dietrich Apr 2007 A1
20070088245 Babaev et al. Apr 2007 A1
20070088346 Mirizzi et al. Apr 2007 A1
20070166357 Shaffer et al. Jul 2007 A1
20070167709 Slayton et al. Jul 2007 A1
20070208253 Slayton et al. Sep 2007 A1
20070219604 Yaroslavsky et al. Sep 2007 A1
20070219605 Yaroslavsky et al. Sep 2007 A1
20070238994 Stecco et al. Oct 2007 A1
20070239075 Rosenberg et al. Oct 2007 A1
20070239079 Manstein et al. Oct 2007 A1
20070239142 Altshuler et al. Oct 2007 A1
20080027328 Klopotek et al. Jan 2008 A1
20080039724 Seip et al. Feb 2008 A1
20080071255 Barthe et al. Mar 2008 A1
20080086054 Slayton et al. Apr 2008 A1
20080097253 Pederson Apr 2008 A1
20080139974 Da Silva Jun 2008 A1
20080146970 Litman et al. Jun 2008 A1
20080167556 Thompson et al. Jul 2008 A1
20080183077 Moreau-Gobard et al. Jul 2008 A1
20080188745 Chen et al. Aug 2008 A1
20080195000 Spooner et al. Aug 2008 A1
20080200810 Buchalter Aug 2008 A1
20080200813 Quistgaard Aug 2008 A1
20080214966 Slayton et al. Sep 2008 A1
20080221491 Slayton et al. Sep 2008 A1
20080223379 Stuker et al. Sep 2008 A1
20080243035 Crunkilton Oct 2008 A1
20080269608 Anderson et al. Oct 2008 A1
20080275342 Barthe et al. Nov 2008 A1
20080281206 Bartlett et al. Nov 2008 A1
20080281236 Eshel et al. Nov 2008 A1
20080281237 Slayton et al. Nov 2008 A1
20080281255 Slayton et al. Nov 2008 A1
20080294073 Barthe et al. Nov 2008 A1
20080319356 Cain et al. Dec 2008 A1
20090005680 Jones et al. Jan 2009 A1
20090012394 Hobelsberger et al. Jan 2009 A1
20090043198 Milner et al. Feb 2009 A1
20090043293 Pankratov et al. Feb 2009 A1
20090069677 Chen et al. Mar 2009 A1
20090093737 Chomas et al. Apr 2009 A1
20090156969 Santangelo Jun 2009 A1
20090171252 Bockenstedt et al. Jul 2009 A1
20090177122 Peterson Jul 2009 A1
20090177123 Peterson Jul 2009 A1
20090182231 Barthe et al. Jul 2009 A1
20090216159 Slayton et al. Aug 2009 A1
20090226424 Hsu Sep 2009 A1
20090227910 Pedersen et al. Sep 2009 A1
20090253988 Slayton et al. Oct 2009 A1
20090299175 Bernstein et al. Dec 2009 A1
20090318909 Debenedictis et al. Dec 2009 A1
20100011236 Barthe et al. Jan 2010 A1
20100022919 Peterson Jan 2010 A1
20100022922 Barthe et al. Jan 2010 A1
20100042020 Ben-Ezra Feb 2010 A1
20100049178 Deem et al. Feb 2010 A1
20100063422 Hynynen et al. Mar 2010 A1
20100130891 Taggart et al. May 2010 A1
20100160782 Slayton et al. Jun 2010 A1
20100160837 Hunziker et al. Jun 2010 A1
20100168576 Poland et al. Jul 2010 A1
20100191120 Kraus et al. Jul 2010 A1
20100241035 Barthe et al. Sep 2010 A1
20100280420 Barthe et al. Nov 2010 A1
20100286518 Lee et al. Nov 2010 A1
20110040171 Foley et al. Feb 2011 A1
20110040190 Jahnke et al. Feb 2011 A1
20110087099 Eshel et al. Apr 2011 A1
20110087255 Mccormack et al. Apr 2011 A1
20110112405 Barthe et al. May 2011 A1
20110178444 Slayton et al. Jul 2011 A1
20110190745 Uebelhoer et al. Aug 2011 A1
20110264012 Lautzenhiser et al. Oct 2011 A1
20120004549 Barthe et al. Jan 2012 A1
20120016239 Barthe et al. Jan 2012 A1
20120029353 Slayton et al. Feb 2012 A1
20120035475 Barthe et al. Feb 2012 A1
20120035476 Barthe et al. Feb 2012 A1
20120046547 Barthe et al. Feb 2012 A1
20120053458 Barthe et al. Mar 2012 A1
20120111339 Barthe et al. May 2012 A1
20120143056 Slayton et al. Jun 2012 A1
20120165668 Slayton et al. Jun 2012 A1
20120165848 Slayton et al. Jun 2012 A1
20120197120 Makin et al. Aug 2012 A1
20120197121 Slayton et al. Aug 2012 A1
20120215105 Slayton et al. Aug 2012 A1
20120271294 Barthe et al. Oct 2012 A1
20120296240 Azhari et al. Nov 2012 A1
20120316426 Foley et al. Dec 2012 A1
20120330197 Makin et al. Dec 2012 A1
20120330222 Barthe et al. Dec 2012 A1
20120330223 Makin et al. Dec 2012 A1
20130012755 Slayton Jan 2013 A1
20130012816 Slayton et al. Jan 2013 A1
20130012838 Jaeger et al. Jan 2013 A1
20130012842 Barthe Jan 2013 A1
20130018286 Slayton et al. Jan 2013 A1
20130310863 Barthe et al. Jan 2013 A1
20130046209 Slayton et al. Feb 2013 A1
20130066208 Barthe et al. Mar 2013 A1
20130066237 Smotrich et al. Mar 2013 A1
20130072826 Slayton et al. Mar 2013 A1
20130096471 Slayton et al. Apr 2013 A1
20130190659 Slayton et al. Jul 2013 A1
20130211258 Barthe et al. Aug 2013 A1
20130281853 Slayton et al. Oct 2013 A1
20130281891 Slayton et al. Oct 2013 A1
20130296697 Slayton et al. Nov 2013 A1
20130296700 Slayton et al. Nov 2013 A1
20130303904 Barthe et al. Nov 2013 A1
20130303905 Barthe et al. Nov 2013 A1
20140082907 Barthe Mar 2014 A1
20140142430 Slayton et al. May 2014 A1
20140148834 Barthe et al. May 2014 A1
20140180174 Slayton et al. Jun 2014 A1
20140187944 Slayton et al. Jul 2014 A1
20140188015 Slayton et al. Jul 2014 A1
20140188145 Slayton et al. Jul 2014 A1
Foreign Referenced Citations (94)
Number Date Country
4029175 Mar 1992 DE
10140604 Mar 2003 DE
10219217 Nov 2003 DE
10219297 Nov 2003 DE
20314479 Mar 2004 DE
0344773 Dec 1989 EP
1479412 Nov 1991 EP
0473553 Apr 1992 EP
0661029 Jul 1995 EP
1050322 Nov 2000 EP
1234566 Aug 2002 EP
1262160 Dec 2002 EP
1374944 Jan 2004 EP
2113099 Aug 1983 GB
63036171 Feb 1988 JP
03048299 Mar 1991 JP
3123559 May 1991 JP
03136642 Jun 1991 JP
4089058 Mar 1992 JP
04150847 May 1992 JP
7080087 Mar 1995 JP
07505793 Jun 1995 JP
7222782 Aug 1995 JP
09047458 Feb 1997 JP
11505440 May 1999 JP
11506636 Jun 1999 JP
2000166940 Jun 2000 JP
2001170068 Jun 2001 JP
2002078764 Mar 2002 JP
2002515786 May 2002 JP
2002521118 Jul 2002 JP
2002537939 Nov 2002 JP
2003050298 Feb 2003 JP
2003204982 Jul 2003 JP
2004147719 May 2004 JP
2005503388 Feb 2005 JP
2005527336 Sep 2005 JP
2005323213 Nov 2005 JP
2006520247 Sep 2006 JP
2007505793 Mar 2007 JP
2009518126 May 2009 JP
2010517695 May 2010 JP
1020010024871 Mar 2001 KR
1020060113930 Nov 2006 KR
1020070065332 Jun 2007 KR
1020070070161 Jul 2007 KR
1020070098856 Oct 2007 KR
1020070104878 Oct 2007 KR
1020070114105 Nov 2007 KR
9625888 Aug 1996 WO
9639079 Dec 1996 WO
WO 9735518 Oct 1997 WO
9832379 Jul 1998 WO
WO 9933520 Jul 1999 WO
WO 9949788 Oct 1999 WO
0006032 Feb 2000 WO
WO 0015300 Mar 2000 WO
WO 0021612 Apr 2000 WO
0053113 Sep 2000 WO
WO 0128623 Apr 2001 WO
WO 0182777 Nov 2001 WO
WO 0182778 Nov 2001 WO
WO 0187161 Nov 2001 WO
0209813 Feb 2002 WO
WO 0209813 Feb 2002 WO
02024050 Mar 2002 WO
WO 0224050 Mar 2002 WO
WO 0292168 Nov 2002 WO
03053266 Jul 2003 WO
03065347 Aug 2003 WO
WO 03070105 Aug 2003 WO
WO 03077833 Sep 2003 WO
03086215 Oct 2003 WO
03096883 Nov 2003 WO
03101530 Dec 2003 WO
2004000116 Dec 2003 WO
WO 03099177 Dec 2003 WO
2004080147 Sep 2004 WO
2004110558 Dec 2004 WO
2005011804 Feb 2005 WO
2005065408 Jul 2005 WO
2005090978 Sep 2005 WO
2006042163 Apr 2006 WO
WO 2006042168 Apr 2006 WO
WO 2006042201 Apr 2006 WO
WO2006036870 Apr 2006 WO
2006065671 Jun 2006 WO
2006082573 Aug 2006 WO
2007067563 Jun 2007 WO
2008024923 Feb 2008 WO
2008036622 Mar 2008 WO
2009013729 Jan 2009 WO
2009149390 Dec 2009 WO
2014055708 Apr 2014 WO
Non-Patent Literature Citations (78)
Entry
Non-Final Office Action mailed Feb. 12, 2007 in U.S. Appl. No. 10/944,500.
Final Office Action mailed Oct. 3, 2008 in U.S. Appl. No. 10/944,500.
Advisory Action mailed Mar. 4, 2009 in U.S. Appl. No. 10/944,500.
Non-Final Office Action mailed Jul. 21, 2009 in U.S. Appl. No. 10/944,500.
Notice of Allowance mailed Mar. 9, 2010 in U.S. Appl. No. 10/944,500.
ISR and Written Opinion mailed Jan. 26, 2006 in Int'l Application No. PCT/US05/033195.
IPRP mail Dec. 22, 2006 in Int'l Application No. PCT/US05/033195.
Examination Report mailed Feb. 19, 2010 in European App. No. 08747803.8.
Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85.
Barthe et al., “Ultrasound therapy system and abiation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.
Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 5, 2005, pp. 9463-9468.
Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444-456.
Daum et al., “Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery,” IEEE Transactions on Ultrasonics, Feroelectronics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438.
Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924.
Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9.
Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153.
Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.
Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2).
Husseini et al. “Investigating the mechanism of accoustically activated uptake of drugs from Pluronic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6.
Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882.
Johnson, S.A., et al., “Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982.
Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.
Makin et al, “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
Makin et al., “Confirmal Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays”, 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.
Manohar et al, “Photoaccoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling nad Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14.
Reid, Gavin, et al., “Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
Righetti et al, “Elastographic Characterization of HIFU-Induced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113.
Mitragotri, Samir; “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4.
Sanghvi, N.T., et al., “Transrectal Ablation of Prostrate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210.
Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fiels,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839.
Smith, Nadine Barrie, et al., “Non-Invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3.
Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49.
Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Aceince, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
Ueno, S., et al., “Ultrasound Thermometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652.
Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
White et al “Selective Creation of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1.
Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages.
Wasson, Scott, “NVIDIA's GeFroce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration from PCT/US2008-062936 mailed Sep. 25, 2008.
International Preliminary Report on Patentability for International application No. PCT/US2008/062936 dated Nov. 19, 2009.
Chen, L. et al., ““Effect of Blood Perfusion on the ablation of liver perenchyma with high intensity focused ultrasound,”” Phys. Med. Biol; 38:1661-1673; 1993b.
Damianou et al., Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery, 1993 IEEE Ultrasound Symposium, pp. 1199-1202.
Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954.
Harr, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993.
Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928.
Madersbacher, S. et al., “Tissue Ablation in Bening Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993.
Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992).
Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med. & Biol. vol. 19, No. 2, pp. 123-125 (1993).
Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67.
Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555.
European Examination Report in related Application No. 05808908.7 dated Jun. 29, 2009.
European Examination Report in related Application No. 05810308.6 dated Jun. 29, 2009.
European Examination Report in related Application No. 10185100.4 dated Jan. 6, 2014.
European Examination Report in related Application No. 10185120.2 dated Jan. 22, 2014.
Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on the pp. 2-5 of the information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046122.
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046123.
International Search Report and Written Opinion dated Jan. 28, 2012 in Application No. PCT/US2012/046327.
International Search Report and Written Opinion dated Jan. 28, 2013 in Application No. PCT/US2012/046125.
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001361.
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001362.
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001366.
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001367.
Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600.
International Search Report and Written Opinion dated Mar. 28, 2012 in Application No. PCT/US2011/001362.
Calderhead et al., One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell, Laser Therapy, Jul. 2008, pp. 141-148, 17.3.
European Examination Report in related Application No. 09835856.7 dated Apr. 11, 2004.
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001366.
PCT International Search Report and Written Opinion, PCT/US2014/030779, Sep. 1, 2014, 8 pages.
European Patent Office, Examination Report, EP 07814933.3, Aug. 5, 2014, 5 pages.
European Patent Office, Examination Report, EP 05798870.1, Oct. 20, 2014, 5 pages.
European Patent Office, Examination Report, EP 10185100.4, Oct. 24, 2014, 4 pages.
European Patent Office, Examination Report, EP 10185112.9, Oct. 24, 2014, 5 pages.
European Patent Office, Examination Report, EP 10185117.8, Oct. 24, 2014, 5 pages.
European Patent Office, Examination Report, EP 10185120.2, Oct. 24, 2014, 4 pages.
Related Publications (1)
Number Date Country
20080221491 A1 Sep 2008 US
Provisional Applications (1)
Number Date Country
60916475 May 2007 US
Continuation in Parts (1)
Number Date Country
Parent 10944500 Sep 2004 US
Child 12116845 US